CompletedNCT01493726

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Medication studyAges 18–55United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Atlanta and 5 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateDecember 2011

Recruitment status: Completed
Enrollment listed in the registry: 88
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT01493726
Official title: Show the full official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Completed

Atlanta · Hoffman Estates · St Louis

3 more locations

FAQ

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.